AGE Research Group, Newcastle University Institute for Translational and Clinical Research, Newcastle upon Tyne, UK.
NIHR Newcastle Biomedical Research Centre, Newcastle University and Newcastle upon Tyne NHS Foundation Trust, 3rd Floor Biomedical Research Building, Campus for Ageing and Vitality, Newcastle upon Tyne, NE4 5PL, UK.
Eur Geriatr Med. 2020 Jun;11(3):433-441. doi: 10.1007/s41999-020-00310-5. Epub 2020 Mar 19.
The European Working Group on Sarcopenia in Older People 2 (EWGSOP2) consensus definition introduced the concept of probable sarcopenia as a basis on which to begin treatment. Our aims were to describe the prevalence of probable sarcopenia in older adults and to investigate the utility of (1) the SARC-F tool and (2) clinical risk factors for the identification of those likely to have probable sarcopenia.
We used data from the 1946 British birth cohort at age 69, with 1686 participants included in the analyses. We used the EWGSOP2 cut points for weak grip strength and slow chair rise time, with the presence of one or both indicating probable sarcopenia. We examined the sensitivity and specificity of the SARC-F tool for probable sarcopenia. We also examined associations between clinical risk factors and probable sarcopenia.
The prevalence of probable sarcopenia was 19%. A SARC-F score of ≥ 4 had low sensitivity (15%) and high specificity (99%) for probable sarcopenia, whereas a score of ≥ 1 had higher sensitivity (65%) and reasonable specificity (72%). Three clinical risk factors were independently associated with probable sarcopenia: polypharmacy [OR 2.7 (95% CI 1.7, 4.2)], lower body osteoarthritis [OR 1.8 (95% CI 1.3, 2.6)] and physical inactivity [OR of 2.1 (95% CI 1.5, 2.8)].
We have shown that EWGSOP2 probable sarcopenia is common in community-dwelling adults in early old age. Those with any positive responses to the questions in the SARC-F tool, a history of polypharmacy, lower body osteoarthritis or physical inactivity should be prioritised for the assessment of muscle strength.
欧洲老年人肌肉减少症工作组 2 (EWGSOP2)共识定义引入了疑似肌肉减少症的概念,作为开始治疗的基础。我们的目的是描述老年人中疑似肌肉减少症的患病率,并探讨(1)SARC-F 工具和(2)临床危险因素在识别可能患有疑似肌肉减少症的人群中的作用。
我们使用了 1946 年英国出生队列在 69 岁时的数据,其中有 1686 名参与者纳入了分析。我们使用了 EWGSOP2 的握力和椅子起坐时间的切点,存在一个或两个指标表明存在疑似肌肉减少症。我们检查了 SARC-F 工具对疑似肌肉减少症的敏感性和特异性。我们还研究了临床危险因素与疑似肌肉减少症之间的关联。
疑似肌肉减少症的患病率为 19%。SARC-F 评分为≥4 对疑似肌肉减少症的敏感性(15%)低,特异性(99%)高,而评分≥1 则具有较高的敏感性(65%)和合理的特异性(72%)。三个临床危险因素与疑似肌肉减少症独立相关:多药治疗[比值比(OR)2.7(95%置信区间 1.7, 4.2)]、下半身骨关节炎[OR 1.8(95%CI 1.3, 2.6)]和身体不活动[OR 2.1(95%CI 1.5, 2.8)]。
我们已经表明,在早期老年的社区居住成年人中,EWGSOP2 疑似肌肉减少症很常见。那些对 SARC-F 工具中的任何一个问题有阳性反应、有药物治疗史、下半身骨关节炎或身体不活动的人,应该优先进行肌肉力量评估。